Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 71.70
+5.70 (8.64%)
At close: Mar 27, 2026
Shanghai Henlius Biotech Market Cap
Shanghai Henlius Biotech has a market cap or net worth of 38.97 billion as of March 27, 2026. Its market cap has increased by 156.07% in one year.
Market Cap
38.97B
Enterprise Value
42.03B
Revenue
7.42B
Ranking
n/a
PE Ratio
42.67
Stock Price
71.70
Market Cap Chart
Since September 25, 2019, Shanghai Henlius Biotech's market cap has increased from 26.66B to 38.97B, an increase of 46.17%. That is a compound annual growth rate of 6.01%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 26, 2026 | 35.87B | 15.69% |
| Dec 31, 2025 | 31.01B | 140.72% |
| Dec 31, 2024 | 12.88B | 70.50% |
| Dec 29, 2023 | 7.55B | 8.59% |
| Dec 30, 2022 | 6.96B | -41.95% |
| Dec 31, 2021 | 11.98B | -53.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| RemeGen | 68.68B |
| 3SBio | 59.89B |
| Biocytogen Pharmaceuticals (Beijing) | 36.79B |
| Shanghai Junshi Biosciences | 35.08B |
| TransThera Sciences (Nanjing) | 27.89B |
| InnoCare Pharma | 26.41B |
| Duality Biotherapeutics | 25.62B |
| Genscript Biotech | 24.27B |